Loading…
Loading…
MDCLF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MDCLF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MDCLF and 80,000+ other tickers.
See exactly how MDCLF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MDCLF and 80,000+ other tickers.
MedinCell S.A. is a pharmaceutical company dedicated to creating a diverse array of medical treatments. At the heart of its innovation is the BEPO platform, a unique technology designed for long-acting injectable drugs. This system utilizes specific proprietary copolymers alongside a compatible solvent to effectively dissolve or suspend active pharmaceutical compounds, ensuring their sustained release within the body. The company's clinical pipeline includes several notable projects: mdc-IRM, a subcutaneous injection intended for schizophrenia, which is currently undergoing late-stage (Phase…
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026. Dr Kim will engage with investors in a fireside discussion led by Piper Sandler analysts at 12:30.
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia.
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced that its Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at the Company's Annual General Meeting on September 30, 2026. A highly experienced international life sciences executive, Dr. Svanberg would bring deep expertise in global pharmaceutical development, governance, executive compensation and global health as Medincell advances its next phase of growth.
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced the completion of non-dilutive financing transactions designed to strengthen its financing profile and align debt maturities with the Company's expected revenue growth trajectory and future cash flows. These cash flows are expected to be primarily driven by milestones and royalties from UZEDY®, which is already marketed, and from Olanzapine LAI, currently under regulatory review in the U.S., with approval ant.
MedinCell S.A. (MDCLF) Q4 2026 Earnings Call Transcript